Literature DB >> 19212852

Teriparatide following bisphosphonates: initial and long-term effects on microarchitecture and bone remodeling at the human iliac crest.

Bjorn Jobke1, Michael Pfeifer, Helmut W Minne.   

Abstract

Since the approval of teriparatide for clinical application, a number of iliac crest studies have focused on increases in bone volume or changes in structural parameters with microCT and numerical changes in histomorphometry. This investigation is based on individual histopathological observations related to early and late effects of teriparatide treatment in humans. A total of 44 (18 paired) iliac crest biopsies (ICB) from 41 patients receiving teriparatide (10 months +/- 6 months) following bisphosphonate (BP) treatment were investigated for hematopoietic changes, bone turnover, and description of microarchitectural changes using histology and selective microCT. Fully 71% of the ICB showed a normal or high bone turnover; 56% of the paired ICB presented an increase in bone turnover following teriparatide treatment. Early teriparatide stimulation (<1 month) resulted in peritrabecular fibroblast-like formations. Rare findings (<9%) included reactive hematopoietic changes, osteoidosis, endosteal fibrosis, microcallus, or woven bone. Round mast cells were frequently observed within marrow spaces. A total of 14% had an increase in cortical porosity, approximately 20% demonstrated signs of intratrabecular resorption sites. Teriparatide treatment resulted in an increase in remodeling units as early as 1 week after the first application with a continuous stimulation up to 18 months of rhPTH treatment despite previous BPs. Subgroups of patients developed increased cortical and/or intratrabecular resorption pattern, with unclear biomechanical significance. This mechanism could potentially result in new trabecular structures with an increase in trabecular number. Some individuals presented histological findings (e.g., fibrosis) that may require adjustment of treatment that could be of importance for clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212852     DOI: 10.1080/03008200802412462

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  5 in total

1.  Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.

Authors:  Adi Cohen; Emily M Stein; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Serge Cremers; Donald J McMahon; Thomas L Nickolas; Ralph Müller; Alexander Zwahlen; Polly Young; Julie Stubby; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

2.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176

3.  Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures.

Authors:  Anas Saleh; Vishal V Hegde; Anish G Potty; Robert Schneider; Charles N Cornell; Joseph M Lane
Journal:  HSS J       Date:  2012-05-02

Review 4.  PTH replacement therapy of hypoparathyroidism.

Authors:  L Rejnmark; T Sikjaer; L Underbjerg; L Mosekilde
Journal:  Osteoporos Int       Date:  2012-11-27       Impact factor: 4.507

5.  Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy.

Authors:  Tsung-Li Lin; Shyu-Jye Wang; Yi-Chin Fong; Chin-Jung Hsu; Horng-Chaung Hsu; Chun-Hao Tsai
Journal:  BMC Res Notes       Date:  2013-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.